Preferred Label : FEC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen;
NCIt synonyms : FEC Followed by Pertuzumab Trastuzumab Paclitaxel; Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab Trastuzumab Paclitaxel; FEC Followed by Paclitaxel/Trastuzumab/Pertuzumab; Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Paclitaxel;
NCIt related terms : FEC-THP (Paclitaxel) (trastuzumab-herw); FEC-THP (Paclitaxel) (trastuzumab-dttb); FEC-THP (Paclitaxel); FEC-THP (Paclitaxel) (trastuzumab-dkst); FEC-THP (Paclitaxel) (trastuzumab-anns); FEC-THP (Paclitaxel) (trastuzumab-zerc); FEC-THP (Paclitaxel) (trastuzumab-qyyp); FEC-THP (Paclitaxel) (trastuzumab-pkrb);
NCIt definition : A regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide,
followed by pertuzumab, trastuzumab and paclitaxel, used as a neoadjuvant or adjuvant
treatment for HER-2/neu-positive breast cancer.;
NCIt note : Source: NCCN Guidelines 2017;
NCI Metathesaurus CUI : CL525013;
Codes from synonyms : 128859; 129247; 128956; 129441; 129344; 129053; 64061; 129150;
Origin ID : C138039;
UMLS CUI : C4527346;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
